Abeona Therapeutics, Inc
Abeona Therapeutics, Inc
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Mucopolysaccharidosis III, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 3A | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT02716246 | |
| Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, skin disorder, vesiculobullous skin disease | Not yet recruiting | Phase 4 | 2026-08-06 | NCT07717736 | |
| A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB | RDEB | Enrolling by invitation | Not stated | 2026-07-17 | NCT05708677 | |
| A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, recessive dystrophic epidermolysis bullosa, skin disorder, vesiculobullous skin disease | Recruiting | Not stated | 2026-07-14 | NCT07700966 | |
| A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Collagen Diseases, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, connective tissue disorder, epidermolysis bullosa, epidermolysis bullosa dystrophica, hereditary disease, hereditary skin disorder, recessive dystrophic epidermolysis bullosa, skin disorder, vesiculobullous skin disease | Active, not recruiting | Phase 3 | 2025-06-27 | NCT05725018 |